C643人甲状腺癌细胞

论文标题： Co-Delivery of 131I and Prima-1 by Self-Assembled CD44-Targeted Nanoparticles for Anaplastic Thyroid Carcinoma Theranostics
DOI： 10.1002/adhm.202001029
发表时间： 2020-12-16
期刊： Advanced Healthcare Materials
影响因子： 7.367
货号： ZQ0321
产品名称： C643 ATC cells

 

论文标题： LncRNA PVT1 Acts as a Tumor Promoter in Thyroid Cancer and Promotes Tumor Progression by Mediating miR-423-5p-PAK3
DOI： 10.2147/CMAR.S283443
发表时间： 2020-12-30
期刊： Cancer Management and Research
影响因子： 2.886
货号： ZQ0321
产品名称： C643 cells

 

 

 

PubMed=2848260; DOI=10.1073/pnas.85.23.9302
Heldin N.-E., Gustavsson B., Claesson-Welsh L., Hammacher A., Mark J., Heldin C.-H., Westermark B.
Aberrant expression of receptors for platelet-derived growth factor in an anaplastic thyroid carcinoma cell line.
Proc. Natl. Acad. Sci. U.S.A. 85:9302-9306(1988)

 

PubMed=14522906
Frasca F., Vella V., Aloisi A., Mandarino A., Mazzon E., Vigneri R., Vigneri P.
p73 tumor-suppressor activity is impaired in human thyroid cancer.
Cancer Res. 63:5829-5837(2003)

 

PubMed=17465858; DOI=10.1089/thy.2006.0246
Lee J.-J., Foukakis T., Hashemi J., Grimelius L., Heldin N.-E., Wallin G., Rudduck C., Lui W.-O., Hoog A., Larsson C.
Molecular cytogenetic profiles of novel and established human anaplastic thyroid carcinoma models.
Thyroid 17:289-301(2007)

 

PubMed=17725429; DOI=10.1089/thy.2007.0097
Meireles A.M., Preto A., Rocha A.S., Rebocho A.P., Maximo V., Pereira-Castro I., Moreira S., Feijao T., Botelho T., Marques R., Trovisco V., Cirnes L., Alves C., Velho S., Soares P., Sobrinho-Simoes M.
Molecular and genotypic characterization of human thyroid follicular cell carcinoma-derived cell lines.
Thyroid 17:707-715(2007)

 

PubMed=18713817; DOI=10.1210/jc.2008-1102
Schweppe R.E., Klopper J.P., Korch C.T., Pugazhenthi U., Benezra M., Knauf J.A., Fagin J.A., Marlow L.A., Copland J.A. III, Smallridge R.C., Haugen B.R.
Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification.
J. Clin. Endocrinol. Metab. 93:4331-4341(2008)

 

PubMed=19087340; DOI=10.1186/1471-2407-8-371
Ribeiro F.R., Meireles A.M., Rocha A.S., Teixeira M.R.
Conventional and molecular cytogenetics of human non-medullary thyroid carcinoma: characterization of eight cell line models and review of the literature on clinical samples.
BMC Cancer 8:371.1-371.11(2008)

 

PubMed=21868764; DOI=10.1158/1078-0432.CCR-11-0690
Zhao M., Sano D., Pickering C.R., Jasser S.A., Henderson Y.C., Clayman G.L., Sturgis E.M., Ow T.J., Lotan R., Carey T.E., Sacks P.G., Grandis J.R., Sidransky D., Heldin N.-E., Myers J.N.
Assembly and initial characterization of a panel of 85 genomically validated cell lines from diverse head and neck tumor sites.
Clin. Cancer Res. 17:7248-7264(2011)

 

PubMed=23833040; DOI=10.1210/jc.2013-2383
Landa I., Ganly I., Chan T.A., Mitsutake N., Matsuse M., Ibrahimpasic T., Ghossein R.A., Fagin J.A.
Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease.
J. Clin. Endocrinol. Metab. 98:E1562-E1566(2013)